VIYASH259.00

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹11,314 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)205.93227.81212.91212.91
Receivable Days (DSO)89.4485.45111.54111.54
Payable Days (DPO)154.80151.78158.33168.17
Cash Conversion Cycle (days)140.57161.48166.12156.28
Working Capital Turnover7.454.222.612.41
Asset Turnover0.890.970.740.74
Cash Conversion (CFO/Net Income)-1.032.581.441.44
CFO/EBITDA0.500.520.490.49
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.